CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...
The convenience and lower cost of the oral pill may be critical to some patients, which could expand the market, improve ...
When people who are overweight and obese stopped taking their weight-loss medications they regained weight faster than those ...
Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments ...
1don MSN
Less than two years after stopping obesity drugs, weight and health issues return, study finds
The retrospective study could not determine whether some patients were more likely than others to keep off the weight.
1don MSNOpinion
Stopping weight-loss jabs leads to much faster rebound than thought—so are they still worth it?
Weight-loss injections, like Wegovy and Mounjaro, have been hailed as gamechangers. In clinical trials, people lost an ...
The research, published in the British Medical Journal on Thursday, adds to a growing body of evidence that suggests ...
Stopping weight loss medication led to weight regain and reversed improvements in cardiometabolic markers in under 2 years, ...
The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth ...
Weight-loss experts reveal their major predictions for 2026, from advanced GLP-1 treatments to AI-driven personalized therapy ...
Obesity is a growing national health crisis, with nearly 40% of U.S. adults affected and about 10% having a severe form of ...
KFF Health News on MSN
California ends Medicaid coverage of weight loss drugs despite TrumpRx plan
Low-income Californians who use Wegovy and similar medications for weight loss lost their coverage at the start of the new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback